Business Context and Reporting Period
Company: Cara Therapeutics, Inc. (CARA)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter ended September 30, 2024
Cara Therapeutics is a biopharmaceutical company focused on treating chronic pruritus. Its lead product, KORSUVA (difelikefalin) injection, is approved for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. In June 2024, the Board approved a streamlined operating plan to explore strategic alternatives after discontinuing its clinical program for oral difelikefalin in notalgia paresthetica (NP) due to lack of efficacy. The company has reduced its workforce by approximately 70% since January 2024 and currently employs only ten people.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $2.6 million | $4.9 million | $5.7 million | $18.0 million |
| Net Loss | $(12.5) million | $(28.0) million | $(63.2) million | $(86.2) million |
| Net Loss Per Share | $(0.23) | $(0.52) | $(1.15) | $(1.59) |
| Cash & Cash Equivalents | $37.1 million | $51.8 million | $37.1 million | $51.8 million |
| Marketable Securities | $5.0 million | $49.0 million | $5.0 million | $49.0 million |
| Total Assets | $51.3 million | $125.8 million | $51.3 million | $125.8 million |
| Shareholders' Equity | $0.7 million | $57.1 million | $0.7 million | $57.1 million |
| Operating Cash Flow (9M) | $(56.9) million | $(74.7) million | $(56.9) million | $(74.7) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 47% in Q3 and 68% in the nine months ended September 30, 2024, compared to the prior year. This was driven by a significant drop in collaborative revenue from KORSUVA sales in the U.S. due to the expiration of the Transition Drug Add-on Payment Adjustment (TDAPA) in April 2024, which led to higher rebates and negative net sales in Q2 2024.
- Non-Cash Revenue: The company recognized $1.3 million in "Other Revenue" in Q3 2024 (non-cash), representing royalty payments earned under agreements with CSL Vifor and Maruishi that are remitted to HCR under a royalty sale agreement. No such revenue was recorded in Q3 2023.
- Expense Reduction: Research and Development (R&D) expenses plummeted 95% in Q3 2024 to $1.4 million (from $25.5 million in Q3 2023) following the discontinuation of clinical programs and workforce reductions.
- Impairment Charges: The company recorded a $4.3 million impairment charge on its right-of-use asset related to the assignment of its corporate lease in September 2024. Additionally, a $1.0 million inventory write-down was recorded due to obsolescence.
- Liquidity Position: Cash and marketable securities decreased significantly from $100.8 million at year-end 2023 to $42.0 million at September 30, 2024, primarily due to operating losses and the maturity of marketable securities.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Alternatives: Management is actively exploring strategic alternatives to maximize shareholder value. There is no assurance that a transaction will be completed or that it will generate value.
- Nasdaq Compliance Risks: The company is not in compliance with Nasdaq listing requirements.
- Bid Price: Granted an extension until January 27, 2025, to maintain a closing bid price of at least $1.00 for 10 consecutive days. Failure to comply may result in delisting.
- Shareholders' Equity: Shareholders' equity was $0.7 million as of September 30, 2024, well below the $2.5 million minimum requirement. The company is assessing options to regain compliance.
- Outlook: Management expects current cash and marketable securities to fund operations for at least the next 12 months. The company anticipates no meaningful revenue contribution from KORSUVA following the TDAPA expiration.
- Unusual Items:
- Restructuring: $5.7 million in restructuring expenses were recorded in the first nine months of 2024 related to workforce reductions.
- Royalty Sale Liability: Non-cash interest expense of $2.0 million (Q3) and $5.9 million (9M) was recorded related to the liability from the sale of future royalties to HCR.
Investor Verification Checklist
- Nasdaq Delisting Risk: Verify the company's progress in regaining compliance with the $1.00 bid price and $2.5 million shareholders' equity requirements by the January 27, 2025 deadline.
- Cash Runway: Confirm the sufficiency of the $42 million in liquid assets to fund the streamlined operating plan and strategic review process for the next 12 months.
- Strategic Transaction Status: Monitor for updates on the exploration of strategic alternatives, including potential mergers, acquisitions, or liquidation.
- KORSUVA Commercial Performance: Assess the long-term impact of the TDAPA expiration on U.S. sales and the company's profit-sharing revenue from CSL Vifor.
- Royalty Sale Agreement (HCR): Review the terms of the royalty sale agreement, specifically the repayment obligations and the impact of the non-cash interest expense on net loss.